AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc.

AGE

AGEAgeX Therapeutics, Inc. US flag

New York Stock Exchange Arca

11.10

USD

-1.50

- -

27.76MMarket Cap

AgeX Therapeutics, Inc.

AGE

(New York Stock Exchange Arca)

Recent

price

11.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Poxel S.A. (0RA2.L)
StemCell Institute Inc. (7096.T)
Nuvation Bio Inc. (NUVB-WT)
Pliant Therapeutics, Inc. (PLRX)
DMS Imaging S.A. (DMSIM.BR)
Innovent Biologics, Inc. (1801.HK)
Business: AgeX Therapeutics, Inc. AgeX Therapeutics, Inc. (AGE) is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases through regenerative medicine and cellular reprogramming technologies. Founded in 2017 and headquartered in Alameda, California, the company offers proprietary platforms including PureStem for generating pluripotent stem cell-derived young cells applicable to degenerative conditions; induced Tissue Regeneration (iTR) to restore regenerative capacity and reverse age-related changes; and cell-based candidates such as AGEX-VASC1 for vascular repair in ischemic tissues and AGEX-BAT1 for metabolic disorders like type II diabetes. It conducts research collaborations, such as with the University of California at Irvine on cellular therapies for neurological disorders, and provides research tools including genomic solutions. In March 2024, AgeX Therapeutics completed a merger with Serina Therapeutics, Inc., under which AgeX changed its name to Serina Therapeutics, Inc. and shifted trading to the NYSE American under the ticker SER, with Serina shareholders retaining majority ownership post-merger; the combined entity now advances Serina's POZ Platform for polymer-drug conjugates, featuring lead candidate SER-252 (POZ-apomorphine) in IND-enabling preclinical studies for advanced Parkinson's disease via subcutaneous injection, alongside SER-270 and expansions into tardive dyskinesia with POZ-VMAT2i. Recent developments for the combined company include securing up to $20 million in funding in September 2025 to support SER-252's registrational trial, positive FDA feedback in August 2025 on its 505(b)(2) pathway, partnerships like a non-exclusive license with Pfizer for POZ in lipid nanoparticle delivery, and a new corporate communications platform launched in October 2025. Operations span the United States with a focus on healthcare and research institutions targeting age-related metabolic, vascular, and neurological indications.

Company News